PamGene
PamGene Awarded €7.5M for Metastatic Cancer Immunotherapy Response Test
The firm said the award from the European Innovation Council's Accelerator program will aid the development and marketing of its IOpener blood test.
PamGene, Alithea Genomics, Lausanne University get €1M for Pan-Cancer Blood Test
The Dutch-Swiss Mainline consortium plans to develop a multiomics model to guide immune checkpoint inhibitor therapy across a broad range of cancers.
The firm is working on more assays to help decide which cancer patients are suitable for immunotherapies and hopes to establish a US-based lab in 2023.
PamGene Gains CE-IVD Registration for Immunotherapy Guidance Tests
The company's blood-based IOpener-NSCLC and IOpener-melanoma assays help guide therapy in non-small cell lung cancer and advanced melanoma patients, respectively.
Netherlands' PamGene Plans to Launch Dx Services for Lung Cancer, Melanoma Treatment Selection
Premium
The company recently expanded its collaboration with Sanquin, the Netherlands' central blood bank, to support its diagnostic development activities.